Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899313 | 0.85 | BRAF (0.57) | BRAFEPHX2RAF1KDR | |
| SCHEMBL5899289 | 0.83 | BRAF (0.57) | BRAFRAF1KDR | |
| SCHEMBL16621229 | 0.77 | NPC1 (0.57) | BRAFEPHX2P2RY1NPC1RAB9A | |
| SCHEMBL19510461 | 0.72 | HPGD (0.53) | BRAFEPHX2NPC1RAB9AKDR | |
| SCHEMBL19510478 | 0.70 | THRB (0.44) | EPHX2P2RY1NPC1RAB9AP2RY14 | |
| SCHEMBL11555827 | 0.69 | EPHX2 (1.00) | EPHX2NPC1RAB9AFAAH | |
| SCHEMBL19510436 | 0.69 | KMT2A (0.50) | — | |
| SCHEMBL19510471 | 0.69 | HPGD (0.49) | EPHX2NPC1RAB9AKDR | |
| SCHEMBL19510395 | 0.69 | MCHR1 (0.51) | EPHX2KDR | |
| SCHEMBL5457073 | 0.69 | RIPK1 (0.36) | BRAFRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | TIE1, UCK2, UTS2R | BRAF 34/4885EPHX2 1290/4885P2RY1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.